Clinical Impact of Pharmaceutical Care Services in Pediatric and Neonatal Intensive Care Unit. Amanda Li Clinical Pharmacist Queen Mary Hospital
|
|
- Neil Johnston
- 6 years ago
- Views:
Transcription
1 Clinical Impact of Pharmaceutical Care Services in Pediatric and Neonatal Intensive Care Unit Amanda Li Clinical Pharmacist Queen Mary Hospital
2 Patient Safety Error pattern unique to the specialty 3 times more at risk for error than adults 1 Immature organs are more sensitive to interventions Impact on growth or other permanent impairment Kaushal R et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001; 285:
3 Medication Safety Medication incidents are not uncommon Sniiders C et al % (N=4846) incidents are medication related Battles JB et al % are medication related
4 80% of the medication incidence occurred during medication ordering Unintended prescription discrepancies - inappropriate dosage - inappropriate drug - inappropriate rate Kaushal R et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001; 285:
5
6 Clinical Pharmacist pharmacists have detected 2-fold more drug related problems than non-pharmacists 1 A ward-based pharmacist could have intercepted 94% of medication incidence in paediatric in-patient setting Shobha P et al. Pharmacists versus Nonpharmacists in Adverse Drug Event Detection: A meta-analysis and systemic review. American Journal of Health-System Pharmacy 2007; 64(8): Kaushal R et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001; 285:
7 Drug Related Problems (DRP) Definition Events or circumstances involving drug therapy that actually or potentially interferes with desired health outcomes Could be sub-therapeutically use of drugs, an unpreventable side effect, or an Adverse Drug Event (ADEs) Strand LM et al. Drug-related problems: their structure and function. DICP 1990; 24(11):
8 DRP-Registration Form V5.01 (PCNE Classification) Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. DICP 1990;24(11):1093-7
9 Pharmaceutical Care Services Pediatric Clinical Pharmacist attached at PNICU Follow ward rounds Timely prescription verification Individual patient monitoring Identification of DRP Provide pharmaceutical interventions
10 Pharmaceutical Interventions Propagate safe & evidence-based drug therapy through collaborative care - prescriber level - patient level - drug level Bed side precautions, on site education
11 Pharmaceutical Interventions Level Drug Patient Scope therapeutic drug monitoring formulation assess drug compliance counsel on medications Prescriber manage health believes participate to implement & monitor a drug therapy suggest for modification or optimization
12 Drug Selection DDX: Acinobacter Pneumonia (d29, 31+5, 1.19kg) Augmentin 35mg IV Q8H Unasyn 60mg IV Q8H
13 Dose Selection DDX: ESBL E Coli Meningitis Meropenem 50mg IV Q8H (2.5kg infant) Meropenem 100mg IV Q8H
14 Drug Use Process DDX: Post liver transplant d2 No immunosuppresent on prescription! (6kg child) Methylprednisolone 18mg IV Q6H
15 Service Outcome May Mar 2012 others Provision of information regarding previous drug history Provision of information regarding administration/ reconstitution Others Streamline antibiotic choice Adjustment in route of administration (IV <-> PO) Drug discontinuation due to contraindication Drug discontinuation due to inactive indication 10.1% Identification/ avoidance of adverse drug reactions Identification/ avoidance of drug interaction or drug incompatibility Laboratory test recommended for drug monitoring 15.1% Drug recommendation to indication Drug recommendation to better alternatives Other dosage adjustment recommendations Dosage adjustment to convenient pack size Dosage adjustment with pharmacokinetic profiles Dosage adjustment with hepatic failure Dosage adjustment with renal failure Dosage adjustment with BW and clinical condition N= 100 Types of Drug Related Problems (DRP) 13.1% 19%
16 Outcome of Intervention Acceptance: 93% Compare to the centralized pharmaceutical services more DRP found 0 Pediatric Clin Pharm Centralized Clin Pharm
17 Unintended Prescription Discrepancies From May 2011-Mar 2012 Inappropriate Dosing Frequency 19% Wrong Drug Identity 15% N= 26 Inappropriate dosage Selection 66% More than 10 fold under or overdose 11.5% (N=3)
18 10 fold error Benzylpenicillin 350,000unit IV Q12H -> 35,000unit IV Q12H (0.35kg premature infant; dosage: 100,000unit/kg/dose) Phenytoin 5mg IV Q12H -> 65mg IV Q12H (13kg child; dosage: 5mg/kg/dose) Ranitidine 10mg IV Q8H -> 1mg IV Q8H (1mg neonate; dosage: 1mg/kg/dose)
19 Summary Ward-based pharmaceutical services is more successful in prescription monitoring % prescription are 10 fold error More effective in identification of DRP Pharmaceutical interventions yield satisfactory acceptance Promote drug therapy optimization with maximum safety
20 Let s support the sick child Questions and Comments
An Evaluation of the Interventions of Clinical Pharmacists at University Hospital of the West Indies
An Evaluation of the Interventions of Clinical Pharmacists at University Hospital of the West Indies PRESENTER : Antia Walcott-Mitchell PHARM D, RPH tiawally@yahoo.com June 2013 Contributors Dr. Delmore
More informationPharmacotherapy Issues in the Pediatric Population
Pharmacotherapy Issues in the Pediatric Population Continuing Professional Pharmacy Development Dr. Shane Pawluk, PharmD Dr. Andrea Cartwright, PharmD Dr. Maryam Khaja March 26, 2014 Outline Didactic Session
More informationTHE ADVANCED MEDICATION REVIEW
THE ADVANCED MEDICATION REVIEW PCNE WORKING SYMPOSIUM ON MEDICATION REVIEW 2009 WORKSHOP 3 Facilitator: Nina Griese n.griese@abda.aponet.de Aim of the workshop 2 To define an advanced medication review
More informationEvaluation of Oncology Pharmacist Therapeutic Recommendations in the Oncology Wards and Clinics at Princess Margaret Hospital
Evaluation of Oncology Pharmacist Therapeutic Recommendations in the Oncology Wards and Clinics at Princess Margaret Hospital Elton Yip Pharmacist Princess Margaret Hospital at PMH Pilot service started
More informationPPP 1. Continuation, modification, and discontinuation of a medication
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationClassification for Drug related problems
Classification for Drug related problems V8.02 2003-2017 Pharmaceutical Care Network Europe Foundation This classification can freely be used in Pharmaceutical Care Research and practice, as long as the
More informationDevelopment of clinical pharmacy services for intensive care units in Korea
Kim et al. SpringerPlus 2014, 3:34 a SpringerOpen Journal RESEARCH Open Access Development of clinical pharmacy services for intensive care units in Korea Jeong Mee Kim 1,2, So Jin Park 2, You Min Sohn
More informationThe University of Jordan
The University of Jordan Faculty: Faculty of pharmacy Department: Department of Biopharmaceutics and Clinical pharmacy Program: Pharm D Academic Year/ Semester: Spring 2014/2015 Course Name (Course Number):
More informationIslamic University Jl. Gajayana No. 50 Malang University Jl. Gajayana No. 50 Malang 6514
23 IDENTIFICATION OF POTENTIAL DRUG RELATED PROBLEMS OF IMPROPER DOSAGE AND ADVERSE DRUG REACTIONS CATEGORIES IN OSTEOARTHRITIS OUTPATIENTS IN RSUD JOMBANG 2016 1 Ayu Tria Nurjannah Muslim, 2 *Abdul Hakim,
More informationMEDICATION PRESCRIBING ERRORS IN PAEDIATRIC OUTPATIENTS PRESCRIPTIONS AT A PAEDIATRIC HOSPITAL IN NEPAL
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Sunil et al. SJIF Impact Factor 6.041 Volume 6, Issue 1, 1004-1013 Research Article ISSN 2278 4357 MEDICATION PRESCRIBING ERRORS IN PAEDIATRIC OUTPATIENTS
More informationFrequently Asked Questions
Page 1 Frequently Asked Questions Codeine and all multiple-ingredient products containing codeine are restricted on the AHS Provincial Drug Formulary to patients 18 years of age and older. 1. What does
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT PRIMENE 10% 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each litre of the infusion solution contains: L-Isoleucine L-Leucine L-Valine
More informationOrchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department
Orchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department Dr. Eugene Tso Division of Infectious Diseases Department of Medicine & Geriatrics United Christian Hospital 11 May 2010
More informationContributes to CQC Outcome number: 9&12 Consulted With Post/Committee/Group Date. Pharmacist. Alison Felton Head of Pharmacy/Deputy Chief.
Prescribing paracetamol in adult inpatients at MEHT Type: Clinical Guideline Register No: 18005 Status: Public on ratification Developed in response to: In line with Basildon Contributes to CQC Outcome
More information2. PRESCRIPTION STATUS/RESTRICTION OF SALES TO PHARMACIES ONLY 3. COMPOSITION OF THE MEDICINAL PRODUCT ml of the solution for infusion contain:
Title Page Information June 1999 1 (5) Aminoven infant 10% 1. NAME OF THE MEDICINAL PRODUCT Aminoven infant 10% 2. PRESCRIPTION STATUS/RESTRICTION OF SALES TO PHARMACIES ONLY For sale in pharmacies only
More informationThailand s experience in developing the Reclassification guideline
Ms.Charunee Krisanaphan Pharmacist, Senior Professional level Standards and Regulations Division, Bureau of Control Thai Food and October 22, 2014 Outlines Definition Existed guideline Process of developing
More informationDispensing and administration of emergency opioid antagonist without a
68-7-23. Dispensing and administration of emergency opioid antagonist without a prescription. (a) A pharmacist may dispense an FDA-approved emergency opioid antagonist and the necessary medical supplies
More informationGlaxoSmithKline. Renal impairment. Hepatic impairment
RELENZA GlaxoSmithKline Zanamivir QUALITATIVE AND QUANTITATIVE COMPOSITION Each RELENZA ROTADISK consists of four regularly spaced double foil blisters each containing a white to off-white micronised powder
More informationWHAT IS STRESS? ( C ) L A Y L A C A S S I M E R S C O N S U L T A N T S C C,
WHAT IS STRESS? Many definitions, but a useful one by Professor Richard S. Lazarus (1966): Stress occurs when an individual perceives that the demands of an external situation are beyond his or her perceived
More informationGuidelines on the Administration of Paracetamol in Children
DERBY HOSPITALS NHS FOUNDATION TRUST DIVISION OF INTEGRATED MEDICINE PAEDIATRICS Guidelines on the Administration of Paracetamol in Children REF NO: CH PH GE 17 Reference Number: CH PH GE 17 Version: 5
More informationReport of the Informal Expert Meeting on Dosage Forms of Medicines for Children WHO Headquarters, Geneva, Switzerland
Report of the Informal Expert Meeting on Dosage Forms of Medicines for Children WHO Headquarters, Geneva, Switzerland Comments of the Malta Chamber of Pharmacists 15 th February 2008 The Malta Chamber
More informationComprehensive support for your patients on MYALEPT
Comprehensive support for your patients on MYALEPT Insurance and financial assistance options (see page 3) Fulfillment support (see page 6) Co-pay assistance a,b (see page 4) Your patient Injection training
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationPublic Assessment Report. EU worksharing project paediatric data. Valcyte. Valganciclovir
Public Assessment Report EU worksharing project paediatric data Valcyte Valganciclovir Currently approved indication(s): Pharmaceutical form(s) affected by this project: Strength(s) affected by this variation:
More informationPharmacy 445 Public Health Applications in Pharmacy Jacqueline Gardner, Ph.D. Professor, Department of Pharmacy. Pharmacists Role 1
Pharmacy 445 Public Health Applications in Pharmacy Jacqueline Gardner, Ph.D. Professor, Department of Pharmacy Pharmacists Role 1 Promotion of health improvement, wellness, and disease prevention in cooperation
More informationName Date Period. West Nomogram
West Nomogram A West Nomogram is used to help adjust medication calculations for children. Because children are smaller than adults, they are usually given smaller amounts of medication. The adjustment
More informationPrescriber and Pharmacy Guide for the Tracleer REMS Program
Prescriber and Pharmacy Guide for the Tracleer REMS Program Please see accompanying full Prescribing Information, including BOXED WARNING for hepatotoxicity and teratogenicity. Introduction to Tracleer
More informationIN USE PRODUCT SAFETY ASSESSMENT REPORT FOR COLISTIMETHATE SODIUM
BACKGROUND IN USE PRODUCT SAFETY ASSESSMENT REPORT FOR COLISTIMETHATE SODIUM SUMMARY OF ASSESSMENT AND ITS FINDINGS Colistimethate sodium (colistin sulfomethate sodium) is licensed in the UK to be given
More informationMORPHINE ADMINISTRATION
Introduction Individualised Administration Drug of Choice Route of Administration & Doses Monitoring of Neonates & high risk patients Team Management Responsibility Morphine Protocol Flow Chart Introduction
More informationNBPDP Drug Utilization Review Process Update
Bulletin # 802 December 1, 2010 NBPDP Drug Utilization Review Process Update The New Brunswick Prescription Drug Program (NBPDP) employs a Drug Utilization Review (DUR) process which identifies, investigates
More informationCardiology Pharmacist. Melanie Madorsky, PharmD, BCPS TSHP Annual Meeting April 7, 2018
Cardiology Pharmacist Melanie Madorsky, PharmD, BCPS TSHP Annual Meeting April 7, 2018 Melanie.Madorsky@memorialhermann.org Objectives Explain the daily responsibilities of the Cardiology Pharmacist Identify
More informationThe safety concerns defined with the reference product apply to Buprenorphine-Naloxone 2/0.5 mg, 8/2 mg, sublingual tablets.
These products are indicated in the substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter
More informationTHE AVOIDABLE THERAPEUTICAL COMPLICATIONS IN MEDICAL AND PAEDIATRIC SECTION OF A TEACHING HOSPITAL KPK, PAKISTAN
731 J App Pharm 04(01): 731-738; January, 2013 Muhammad et al., 2013 Original Research Article THE AVOIDABLE THERAPEUTICAL COMPLICATIONS IN MEDICAL AND PAEDIATRIC SECTION OF A TEACHING HOSPITAL KPK, PAKISTAN
More informationDisclosure. Screening for adverse drug events: a tool to improve safe medication use
Screening for adverse drug events: a tool to improve safe medication use John T. Holmes, PharmD, BCPS Assistant Professor Departments of Family Medicine and Pharmacy Practice Idaho State University Disclosure
More informationGuidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance
More informationPRINCIPLES OF PEDIATRIC PHARMACOTHERAPY. Marianne Krupicka, Pharm.D. Oregon Health and Science University/ Doernbecher Children s Hospital
PRINCIPLES OF PEDIATRIC PHARMACOTHERAPY Marianne Krupicka, Pharm.D. Oregon Health and Science University/ Doernbecher Children s Hospital References Pediatric Lexicomp Harriett Lane Respiratory Rate Newborn
More informationReport on Investigation Results
Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this
More informationAssessment of Medication-Related Problems in Geriatric Patients of a Rural Tertiary Care Hospital
Pharmacy Practice Assessment of Medication-Related Problems in Geriatric Patients of a Rural Tertiary Care Hospital Ramanath KV, Nedumballi S Department of Pharmacy Practice, Sri Adichunchanagiri College
More informationTrust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults
A clinical guideline recommended for use: In: By: For: Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name of document author s Line Manager: Job
More informationPAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain
Index No: MMG43 PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain Version: 3.1 (Includes anti-emetics and naloxone) Date ratified: July 2013 Ratified by: (Name of Committee) Name
More informationAnnotation Guidelines for the Adverse Drug Event (ADE) and Medication Extraction Challenge
Annotation Guidelines for the Adverse Drug Event (ADE) and Medication Extraction Challenge 1. Overview Written by Kevin Buchan Edited by Marilena Di Bari and Amber Stubbs The task hereby proposed is aimed
More informationDeterminants and frequency of pharmaceutical compounding in pharmacy practice in Palestine
Research Paper Determinants and frequency of pharmaceutical compounding in pharmacy practice in Palestine Abdel Naser Zaid a, Rowa Al-Ramahi b, Qusai Shahed c, Belal Saleh c and Josephean Elaraj b Departments
More informationB. PACKAGE LEAFLET. Page 1 of 6
B. PACKAGE LEAFLET Page 1 of 6 PACKAGE LEAFLET Prilocard 1.25 mg, 2.5 mg, 5 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE
More informationROSOBAC-1GM / ROSOBAC-FORT
ROSOBAC-1GM / ROSOBAC-FORT ROSOBAC - 1GM. COMPOSITION : Each vial contains Sterile Cefoperazone Sodium IP Eq. to Anhydrous Cefoperazone - Sterile Sulbactam Sodium USP Eq. to Anhydrous Sulbactam - ROSOBAC
More informationPackage leaflet: Information for the patient. Tranexamic Acid 100 mg/ml, Solution for Injection tranexamic acid
Package leaflet: Information for the patient Tranexamic Acid 100 mg/ml, Solution for Injection tranexamic acid Read all of this leaflet carefully before you are given this medicine because it contains
More informationAWARENESS OF DENTISTS ABOUT MEDICATION ERRORS
AWARENESS OF DENTISTS ABOUT MEDICATION ERRORS Sangeetha P 1, Prabhawati P I 2, Inamadar P I 3, HOW TO CITE THIS ARTICLE: Sangeetha P, Prabhawati PI, Inamadar PI,. Awareness of dentists about medication
More informationBasic Principles in Pharmacology
L. 1 Dr. Mohammed AL-Zobaidy Basic Principles in Pharmacology Learning objectives: by the end of this lecture you should Understand the possible uses of drugs. Explain why a drug has different names. Identify
More informationPresentation of a specific research project
Presentation of a specific research project Appropriate use of medicines in care of the elderly: Factors underlying inappropriateness, and impact of the clinical pharmacist Anne Spinewine 04.10.2011 WBI-
More informationA Nondepolarizing Neuromuscular Blocking (NMB) Agent
DOSING GUIDE A Nondepolarizing Neuromuscular Blocking (NMB) Agent Easy to remember dosing for the 0.20 mg/kg adult intubating doses of NIMBEX 1 *: For every 10 kg, give 1 ml of NIMBEX (2 mg/ml concentration)
More informationCriteria for Registering as Paediatric Neurologist in Malaysia
Criteria for Registering as Paediatric Neurologist in Malaysia A doctor can request to be registered as a paediatric neurologist if he/she fulfils ALL the following requirements: 1 A recognised basic medical
More information1. A patient receives the wrong drug (ex. verified Amox 875 drug dispensed should have been Augmentin 875)
July 12, 2018 Topic: Errors and Omissions Medications errors are made everyday. It is the job of the Pharmacist to prevent these errors from occurring. The right drug to the right patient at the right
More informationMedicines Optimisation Strategy
Clinical Reducing Dosing Errors with Opioid Medicines (Controlled Drug SOP): Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic
More informationEvelina London Children s Hospital (ELCH)
Evelina London Children s Hospital (ELCH) Lead Consultant Jenny Handforth PID Pharmacist Faye Chappell Paediatric OPAT CNS Vacant Overview Paediatric OPAT in London Paediatric OPAT ELCH Children s Hospital
More informationPharmaceutical Management Medicaid 2019
Pharmaceutical Management Medicaid 2019 Toll-free Contact Number: (888) 327-0671 Pharmacy Administration: (810) 244-1660 Introduction Pharmaceutical Management promotes the use of the most clinically appropriate,
More informationPharmacovigilance Methods and Post-Authorisation Safety Studies
Pharmacovigilance Methods and Post-Authorisation Safety Studies Alex Dodoo Director, WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance Accra, Ghana Objectives At the end of this module
More informationClinical Calculation 5 th Edition
Clinical Calculation 5 th Edition Chapter 12 Pediatric Dosage Pages 211-232 Pediatric Dosage There are several methods for calculating pediatric medication dosage based on various combinations of age,
More informationDRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT
c t DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to September 22, 2014. It is intended
More informationDATA SHEET 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
DATA SHEET 1 PRODUCT NAME 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sachet, each 5.1g sachet contains: Sodium chloride 470mg, potassium chloride 300mg, sodium acid citrate 530mg, glucose 3.56g. Tablet,
More informationProcedure Reviewed By: Narinder Sangha Deputy Chief Pharmacist STANDARD OPERATING PROCEDURE
Written By: Objective By: ed By: To ensure safe and consistent working practice throughout Black Country Partnership Foundation Trust (BCPFT) and to avoid unnecessary harm to patients on lithium therapy
More informationMesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections
Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative
More informationEmpowering Older Adults On Drug Adherence A Collaborative Service Model. Cheng Po-po, Peggy Nurse Consultant (Gerontology) Yan Chai Hospital, KWC, HA
Empowering Older Adults On Drug Adherence A Collaborative Service Model Cheng Po-po, Peggy Nurse Consultant (Gerontology) Yan Chai Hospital, KWC, HA Introduction Older adults have multiple pathologies
More informationRegulatory incentives: Experience from European Medicines Agency
Regulatory incentives: Experience from European Medicines Agency European Medicines Agency Presented by: Nathalie Seigneuret An agency of the European Union EU Paediatric Regulation: Objectives Improve
More informationPCNE Classification PCNE scheme for Drug related problems-2
PCNE Classification PCNE scheme for Drug related problems-2 (revised V2.04) PCNE Classification scheme for Drug related problems-page 1 The Problems Primary Domain Code Code Lack of Drug P1.1 1 Patient
More informationTo Take or Not To Take?
To Take or Not To Take? Assessment Question How do the terms adherence & compliance differ? 1. The terms are synonymous 2.Adherence assumes collaboration between patient & provider while compliance suggests
More information247 CMR BOARD OF REGISTRATION IN PHARMACY
247 CMR 18.00: NON-STERILE COMPOUNDING Section 18.01: Authority and Purpose 18.02: Non-Sterile Compounding Process 18.03: Non-Sterile Compounding Facility 18.04: Non-Sterile Compounding Equipment 18.05:
More informationGuideline for the Management of Continuous IV Vancomycin Infusion in Neonates on NICU A Clinical Guideline recommended for use
Guideline for the Management of Continuous IV Vancomycin Infusion in A Clinical Guideline recommended for use For Use in: By: For: Division responsible for document: Key words: Name and job title of document
More informationUsing the BNF. CWFS F1 Programme Safe Prescribing Module
Using the BNF CWFS F1 Programme Safe Prescribing Module Know Your BNF Guidance on prescribing - Controlled drugs and dependence - Prescribing in palliative care/elderly/children Emergency treatment of
More informationFarmadol. Paracetamol 10 mg/ml INFUSION SOLUTION
Farmadol Paracetamol 10 mg/ml INFUSION SOLUTION Composition Each ml contains: Paracetamol 10 mg Pharmacology Pharmacodynamic properties The precise mechanism of the analgesic and antipyretic properties
More informationQuintana Bárcena P, Lord A, Lizotte A, Jouini G, Berbiche D, Lalonde L
Quintana Bárcena P, Lord A, Lizotte A, Jouini G, Berbiche D, Lalonde L Patricia Quintana Bárcena Ph.D candidate in pharmaceutical sciences Faculty of Pharmacy University of Montreal Pharmaceutical Care
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT DigiFab, 40 mg/vial digoxin immune Fab, Powder for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each glass vial
More informationALUNBRIG (brigatinib) Dosing Guide
ALUNBRIG (brigatinib) Dosing Guide INDICATION ALUNBRIG (brigatinib) is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
More informationSurgical antibiotic prophylaxis at Epworth Healthcare
Surgical antibiotic prophylaxis at Epworth Healthcare Dr Joseph Doyle MPH PhD FRACP Infectious Diseases Physician Epworth, Alfred Health & Melbourne Health Senior Lecturer & NHMRC Clinical Research Fellow,
More informationPrepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
More informationPart VI: Summary of the risk management plan by product
Part VI: Summary of the risk management plan by product VI.1 Elements for summary tables in the EPAR VI.1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Hepatotoxic
More informationFIP GUIDELINES Pharmaceutical Research in Paediatric Patients
Adopted by the FIP Council as an FIP statement of policy in Vienna in 2000, transformed to guidelines in 2014 FIP GUIDELINES Pharmaceutical Research in Paediatric Patients Introduction For many medicines,
More informationPractical examples of PDCO advice on development programme; presentation of various case studies
Safeguarding public health Practical examples of PDCO advice on development programme; presentation of various case studies Matthew Thatcher Clinical Assessor at MHRA UK Paediatric Committee delegate A
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT DigiFab (referred to as DIGIFAB) 40 mg/vial digoxin immune Fab, Powder for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationLong Term Care Formulary HCD - 08
1 of 5 PREAMBLE Opioids are an important component of the pharmaceutical armamentarium for management of chronic pain. The superiority of analgesic effect of one narcotic over another is not generally
More informationDocument ref. no: Trust Policy and Procedure. PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy
Document ref. no: Trust Policy and Procedure PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy For use in: For use by: For use for: Document owner: Status: All Clinical Areas
More informationNEXAVAR (sorafenib tosylate) oral tablet
NEXAVAR (sorafenib tosylate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationAmino Acids and Sorbitol injection with/without Electrolytes NIRMIN *
For the use of a registered medical practitioner or a Hospital or a Laboratory only Amino Acids and Sorbitol injection with/without Electrolytes NIRMIN * DESCRIPTION: NIRMIN * is a clear, colourless injection
More informationPATIENT SAFETY ALERT
PATIENT SAFETY ALERT PROBLEM: Research in UK and elsewhere has identified a risk to patients from errors occurring during intravenous administration of potassium solutions. Potassium chloride concentrate
More informationPATIENT INFORMATION LEAFLET. DOTAREM mg/ml, solution for injection (Gadoteric acid)
PATIENT INFORMATION LEAFLET DOTAREM 279.32 mg/ml, solution for injection (Gadoteric acid) Read all this leaflet carefully before you start using this medicine because it contains important information
More informationEasyComp. The TPN Compatibility Software. Clinical Nutrition
EasyComp The TPN Compatibility Software Clinical Nutrition Content 1. General Information 5 1.1 What is EasyComp? 4 1.2 Features and functions of EasyComp 5 1.3 IT requirements 5 t2. Starting EasyComp
More informationOutline. Pharmacists Improving Outcomes in the Management of. of Infectious Diseases. Threats Against Desired Outcomes 7/11/2010
Pharmacists Improving Outcomes in the Management of Infectious Diseases Christine Teng, MSc(Clin Pharm) BCPS Assistant Professor Dept of Pharmacy, National University of Singapore Principal Pharmacist
More informationDrug Prescribing. Ravi Menon
Drug Prescribing Ravi Menon Introduction Approximately 7,000 individual drug doses are administered each day in a 'typical' NHS hospital, 70% of which are prescribed by first year graduates and senior
More information2. Is this request for a preferred medication? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationPrescribe appropriate immunizations for. Prescribe childhood immunization as per. Prescribe influenza vaccinations in high-risk
Supplemental Digital Appendix 1 46 Health Care Problems and the Corresponding 59 Practice Indicators Expected of All Physicians Entering or in Practice Infectious and parasitic diseases Avoidable complications/death
More informationUSER'S GUIDE CANCER DRUG MANUAL DRUG MONOGRAPH: Updated: November 1, 2015
USER'S GUIDE Updated: November 1, 2015 The Cancer Drug Manual provides concise, evaluative drug information on drugs used in an oncology setting. The first edition of the Cancer Drug Manual was published
More informationIndustry Perspective on Formulation and Packaging Considerations
Industry Perspective on Formulation and Packaging Considerations Ron Ogilvie (Pfizer) EFPIA February 2012 1 Industry Perspective on Formulation and Packaging Considerations Provide an overview of formulation
More informationDevelopment of a Medication Discrepancy Classification System to Evaluate the Process of Medication Reconciliation (Work in progress)
Development of a Medication Discrepancy Classification System to Evaluate the Process of Medication Reconciliation (Work in progress) Presented by Enas Almanasreh Supervisors: A/Prof. Timothy F Chen A/Prof.
More informationAllergy Status Identification And Documentation
Allergy Status Identification And Documentation Basic Medication Safety (BMS) Certification Course King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs Learning
More informationUtah. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Utah Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationPractice Direction Standard of Practice # 5: Administration of Drugs including Vaccines
Practice Direction Standard of Practice # 5: Administration of Drugs including Vaccines 1.0 Scope and Objective: 1.1 Expected Outcome This document is a practice direction by Council concerning the implementation
More informationIdentifying and reducing medication errors in mental health
Identifying and reducing medication errors in mental health Hilary Scott Chief Pharmacist South Essex Partnership University NHS Trust with valuable input from Ian Maidment, Senior Lecturer in Clinical
More informationNorth of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines
\ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents
More informationA Layperson s Guide to Pediatric Formulation Development
A Layperson s Guide to Pediatric Formulation Development Karen C. Thompson PhD Senior Principal Scientist Preclinical Development Merck Research Laboratory West Point, Pennsylvania Martin J. Gartland PhD
More informationISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque, NM. [ NMAC - N, ; A, ]
TITLE 16 CHAPTER 19 PART 26 OCCUPATIONAL AND PROFESSIONAL LICENSING PHARMACISTS PHARMACIST PRESCRIPTIVE AUTHORITY 16.19.26.1 ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. A 2.5ml single-dose bottle containing IU Cholecalciferol (equivalent to 625 micrograms vitamin D 3 )
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fultium 25 000 IU Oral Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION A 2.5ml single-dose bottle containing 25 000 IU Cholecalciferol
More information